Stockscreener 앱 받기
0.4202
8.65%
-0.0398
Silexion Therapeutics Corp 주식(SLXN)의 최신 뉴스
Silexion Therapeutics (SLXN) seeks huge share boost and reverse split to stay on Nasdaq - Stock Titan
Silexion Q2 EPS $(5.17) misses $(2.12) estimate; loss widens - scanx.trade
Silexion Therapeutics Raises $35 Million in August Public Offering - Minichart
Silexion Therapeutics Corp 2Q 2026: Net loss $3.55M, EPS $(12.41) — 10-Q Summary - TradingView
Silexion Initiates Phase 2/3 Pancreatic Cancer Trial on July 29 - Minichart
Silexion Therapeutics Reports Second Quarter 2026 Financial Results And Provides Business Update - TradingView
Silexion Reports $3.6 Million Second-Quarter Net Loss as SIL204 Trial Starts - Quiver Quantitative
Silexion Therapeutics reports Q2 2026: $3.6M Q2 net loss, $2.2M cash at June 30 - TradingView
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo! Finance Canada
Silexion Completes 1-for-10 Reverse Share Split - Minichart
Top Silexion Therapeutics CorpWarrant (SLXNW) Competitors 2026 - marketbeat.com
Form 8K Silexion Therapeutics Corp For: 13 August By Investing.com - Investing.com Nigeria
Silexion Therapeutics Executes Reverse Share Split Amid Strain - TipRanks
Silexion Therapeutics Closes Public Offering and Strengthens Equity - TipRanks
Silexion Therapeutics Corp (SLXN) investors report 0% holding but retain warrants - Stock Titan
Silexion Therapeutics Corp SEC Filing (Aug 12, 2026) - Stock Titan
Silexion Therapeutics Prices $2.5 Million Securities Offering; Shares Down Pre-Bell - marketscreener.com
Silexion prices $2.5M offering to fund KRAS cancer trial - Dealroom
Silexion Therapeutics prices $2.5M public offering at $0.65 By Investing.com - Investing.com Nigeria
Silexion Therapeutics prices $2.5M public offering at $0.65 - Investing.com
Silexion Intends to Use Offering Proceeds for Pancreatic Trial - Stock Titan
Silexion Therapeutics Prices $2.5 Million Public Offering of Ordinary Shares and Warrants - Quiver Quantitative
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering - GlobeNewswire
Immunotherapy’s Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN) - TipRanks
Immunotherapy's Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN) - Benzinga
Immunotherapy's Biggest Blind Spot Is A $7 Billion Market. Silexion May Have A Way In (NASDAQ: SLXN) - Menafn
Form 8K Silexion Therapeutics Corp For: 10 August By Investing.com - Investing.com Nigeria
Silexion Updates SIL204 Clinical and Regulatory Roadmap - TipRanks
Silexion Therapeutics (SLXN US): Synthetic Expert Call Transcript (10 Aug 2026) - Smartkarma
Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancers - Bitget
Maxim Group Maintains Silexion Therapeutics(SLXN.US) With Hold Rating - 富途牛牛
IPO Databook: Silexion Therapeutics (SLXN US)Aug 2026 - Smartkarma
Silexion Therapeutics (NASDAQ: SLXN) files S-1 for best-efforts unit sale - Stock Titan
Silexion unveils key SIL204 KRAS preclinical findings - TipRanks
Silexion to present preclinical data on SIL-204 at GI cancer event - Investing.com
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers - The Manila Times
Silexion Therapeutics Reports Preclinical Data Showing SIL204 Immune-Sensitizing Effects in KRAS-Mutant Cancer Cells - Quiver Quantitative
Silexion's SIL204 Alters Three Immune Pathways in Cancer Cells - Stock Titan
Silexion Therapeutics Restores Nasdaq Audit Committee Compliance - TipRanks
Silexion Therapeutics restores Nasdaq audit committee compliance with new appointment - TradingView
Silexion Therapeutics Announces Board Member Resignation - TipRanks
Silexion Therapeutics Warrant (SLXNW) Holds at $0.02 as Range-Bound Trading PersistsVolatility Stop - dars.gov.et
Biomotion Sciences Ordinary Shares (NASDAQ: SLXN) Stock Price, News & Analysis - Kalkine
Amnon Peled resigns from Silexion Therapeutics board effective Aug 1, 2026 - TradingView
Maxim Downgrades Silexion Therapeutics to Hold From Buy - marketscreener.com
Silexion Therapeutics Corp Warrant (SLXNW) Holds Near Par After Modest DeclineHead and Shoulders - dars.gov.et
Silexion Begins Phase 2/3 Trial in Pancreatic Cancer - TipRanks
Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN) - tipranks.com
Silexion Therapeutics Successfully Initiates Phase 2/3 - GlobeNewswire
Silexion Therapeutics Initiates Phase 2/3 Trial for Pancreatic Cancer Drug Candidate - Moomoo
Silexion Activates First Site In Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN) - Menafn
Silexion Therapeutics Corp Revenue Breakdown – NASDAQ:SLXNW - TradingView
Silexion Therapeutics Corp (SLXN) Balance Sheet - TradingKey
Silexion Therapeutics Corp (SLXN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Silexion Therapeutics Corp (SLXN) Cash Flow - TradingKey
Silexion Therapeutics Corp Revenue Breakdown – NASDAQ:SLXN - TradingView
Silexion Therapeutics Corp (SLXN) Income Statement - TradingKey
Silexion Therapeutics Corp (SLXN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Silexion Therapeutics Corp (SLXN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Silexion Therapeutics Corp (SLXN) Institutional Confidence - TradingKey
SLXN|Silexion Therapeutics Corp|Price:2.450|Chg%:+0.180 - TradingKey
SLXN|Silexion Therapeutics Corp|Price:2.460|Chg%:+0.190 - TradingKey
SLXN Price Today: Silexion Therapeutics Corp. Stock Price, Quote & Chart - MEXC
Silexion Therapeutics Shareholders Approve Capital Structure Changes - The Globe and Mail
Silexion Therapeutics (SLXN) Stock Price, News & Analysis - MarketBeat
Silexion Therapeutics announces 1-for-10 reverse share split - MSN
Enterprise value to revenue forward of Silexion Therapeutics Corp – BOATS:SLXN - TradingView
Silexion Therapeutics Company Profile & Introduction - Moomoo
Stock Market News: Ethan Allen Interiors down by 90.10% while Exicure gains 99.48% during mid day trading - Business Upturn
Enterprise value to EBIT forward of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView
Silexion Therapeutics (SLXN) Holds Near Support as Trading Remains SubduedTRIN Signal - dars.gov.et
Price to book forward of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView
0.52%
0.07%
자본화:
|
볼륨(24시간):